Yıl: 2019 Cilt: 3 Sayı: 2 Sayfa Aralığı: 119 - 126 Metin Dili: İngilizce DOI: 10.14744/ejmi.2019.23641 İndeks Tarihi: 01-11-2020

Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality

Öz:
Objectives: This study aims to identify the risk factors associated with 14-day mortality in nosocomial Enterococcibacteremia.Methods: This retrospective study was conducted in a tertiary training hospital. Patients aged 16 or older, with nosoco-mial bacteremia due to Enterococci between January 2012 and January 2018 were included. Analyses were performed using SPSS version 21. Pearson’s chi-square, and Fisher’s Exact tests were used for the comparison of categorical data. Parameters found to be statistically significant in univariate analyses were further tested with multivariate logistic re-gression to predict the risk of mortality. Statistical significance is interpreted as p-values lower than 0.05.Results: The mean age in our study was 64.82±16.76. Patients were diagnosed in intensive care unit (44%), internal medicine wards (41.3%) or surgical wards (14.7%). Reasons of admittance included medical problems (52.7%), surgery (14.1%), cerebrovascular occlusion (12.5%), burns (7.1%) and community acquired infections (6.5%). We found that increase in both Charlson and Pitt bacteremia scores; the presence of neutropenia, severe sepsis, septic shock, or other concurrent infections significantly increased the risk of death. Gentamicin sensitivity yielded more favorable therapeu-tic outcomes regarding mortality.Conclusion: Mortality is higher in patients with higher Charlson comorbidity indices and Pitt bacteremia scores, in neutropenic cases, and patients with concomitant infections and sepsis. Interestingly, mortality in gentamicin-sensitive cases is significantly lower.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
  • 1. Ceci M, Delpech G, Sparo M, Mezzina V, Sánchez BS, Baldaccini B. Clinical and microbiological features of bacteremia caused by Enterococcus faecalis. J Infect Dev Ctries 2015;9:1195–203.
  • 2. Zheng JX, Li H, Pu ZY, Wang HY, Deng XB, Liu XJ, et al. Blood-stream infections caused by Enterococcus spp: A 10-year ret-rospective analysis at a tertiary hospital in China. J Huazhong Univ Sci Technolog Med Sci 2017;37:257–26
  • 3. McBride SJ, Upton A, Roberts SA. Clinical characteristics and outcomes of patients with vancomycin-susceptible Entero-coccus faecalis and Enterococcus faecium bacteraemia—a five-year retrospective review. Eur J Clin Microbiol Infect Dis 2010;29:107–14.
  • 4. Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006-2009: a population-based cohort study. Clin Microbiol Infect 2014;20:145–51.
  • 5. Chuang YC, Chen PY, Lin CY, Chen YC, Wang JT, Chang SC. A retrospective clinical comparison of daptomycin vs dapto-mycin and a beta-lactam antibiotic for treating vancomycin resistant Enterococcus faecium bloodstream infections. Sci Rep 2018;8:1632.
  • 6. Johnstone J, Chen C, Rosella L, Adomako K, Policarpio ME, Lam F, et al. Patient- and hospital-level predictors of vancomycin-resistant Enterococcus (VRE) bacteremia in Ontario, Canada. Am J Infect Control 2018;46:1266–71.
  • 7. Turkish Republic Health Instution Department of Infectious Diseases. Bacteria distribution and antibiotic resistance sur-veillance report for national healthcare-associated infections 2017. Available from: https://infline.saglik.gov.tr/ Accessed 25 February 2019.
  • 8. Kara A, Devrim İ, Bayram N, Katipoğlu N, Kıran E, Oruç Y, et al. Risk of vancomycin-resistant enterococci bloodstream in-fection among patients colonized with vancomycin-resistant enterococci. Braz J Infect Dis 2015;19:58–61.
  • 9. Atalay S, Ece G, Samlıoğlu P, Maraş G, Köse I, Köse S. Evaluation of vancomycin-resistant Enterococcus cases at a tertiary level hospital in Izmir,Turkey. Mikrobiyol Bul 2012;46:553–9.
  • 10. Gedik H, Yıldırmak T, Simşek F, Kantürk A, Arıca D, Aydın D, et al.Vancomycin-resistant enterococci colonization and bac-teremia in patients with hematological malignancies. J Infect Dev Ctries 2014;8:1113–8.
  • 11. Kilbas I, Ciftci IH. Antimicrobial resistance of Enterococcus isolates in Turkey: A meta-analysis of current studies. J Glob Antimicrob Resist 2018;12:26–30
  • 12. Roth JA, Tschudin-Sutter S, Dangel M, Frei R, Battegay M, Wid-mer AF. Value of the Pitt Bacteraemia Score to predict short-term mortality in Staphylococcus aureus bloodstream infec-tion: a validation study. Swiss Med Wkly 2017;147:w14482.
  • 13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic 1987;40:373–83.
  • 14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance def-inition of health care-associated infection and criteria for spe-cific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32.
  • 15. Surviving Sepsis Campaign. International Guidelines for Man-agement of Severe Sepsis and Septic Shock: 2012. Available: http://www.sccm.org/Documents/SSC-Guidelines.pdf. Ac-cessed 25 February 2019.
  • 16. Clinical and Laboratory Standards Institute (2013) Perfor-mance Standards for Antimicrobial Susceptibility Testing, Twenty-Third Informational Supplement. Accessed 25 Febru-ary 2019.
  • 17. Shlaes DM, Levy J, Wolinsky E. Enterococcal bacteremia with-out endocarditis. Arch Intern Med 1981;141:578–81.
  • 18. Malone DA, Wagner RA, Myers JP, Watanakunakorn C. Entero-coccal bacteremia in two large comminity teaching hospital. Am J Med 1986;81:601–4.
  • 19. Maki DG, Agger WAA. Enterococcal bacteremia: Clinical fea-tures, the risk of endocarditis, and management. Medicine. 1988;67:248–69.
  • 20. Lu CL, Chuang YC, Chang HC, Chen YC, Wang JT, Chang SC. Microbiological and clinical characteristics of vancomycin-re-sistant Enterococcus faecium bacteraemia in Taiwan: implica-tion of sequence type for prognosis. J Antimicrob Chemother 2012;67:2243–9.
  • 21. Lagnf AM, Zasowski EJ, Claeys KC, Casapao AM, Rybak MJ. Comparision of clinical outcomes and risk factors in polymi-crobial versus monomicrobial enterococcal bloodstream in-fections. Am J Infect Control 2016;44:917–21.
  • 22. Garrison RV, Fry DE, Berberich S, Polk HC. Enterococcal bac-teremia: Clinical implications and determinants of death. Ann Surg 1982;196:43–7.
  • 23. O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal in-fections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 2015;8:217–30.
  • 24. Orsi GB, Ciorba V. Vancomycin resistant enterococci healthcare associated infections. Ann Ig 2013;25:485–92.
  • 25. Shaked H, Carmeli Y, Schwartz D, Siegman-Igra. Enterococcal bacteraemia: epidemiological, microbiological, clinical and prognostic characteristics, and the impact of high level gen-tamicin resistance. Scand J Infect Dis 2006;38:995–1000.
  • 26. Antalek MD, Mylotte JM, Lesse AJ, Sellick JA. Clinical and molecular epidemiology of Enterococcus faecalis bacteraemia, with special reference to strains with high-level resistance to gentamicin. Clin Infect 1995;20:103–9.
  • 27. Watanakunakorn C, Patel R. Comparison of patients with en-terococcal bacteremia due to strains with and without high-level resistance to gentamicin. Clin Infect Dis 1993;17:74–8.
APA Çalık Ş, ARI A, Tosun S, Okur O, Yiş R (2019). Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. , 119 - 126. 10.14744/ejmi.2019.23641
Chicago Çalık Şebnem,ARI ALPAY,Tosun Selma,Okur Onur,Yiş Reyhan Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. (2019): 119 - 126. 10.14744/ejmi.2019.23641
MLA Çalık Şebnem,ARI ALPAY,Tosun Selma,Okur Onur,Yiş Reyhan Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. , 2019, ss.119 - 126. 10.14744/ejmi.2019.23641
AMA Çalık Ş,ARI A,Tosun S,Okur O,Yiş R Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. . 2019; 119 - 126. 10.14744/ejmi.2019.23641
Vancouver Çalık Ş,ARI A,Tosun S,Okur O,Yiş R Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. . 2019; 119 - 126. 10.14744/ejmi.2019.23641
IEEE Çalık Ş,ARI A,Tosun S,Okur O,Yiş R "Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality." , ss.119 - 126, 2019. 10.14744/ejmi.2019.23641
ISNAD Çalık, Şebnem vd. "Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality". (2019), 119-126. https://doi.org/10.14744/ejmi.2019.23641
APA Çalık Ş, ARI A, Tosun S, Okur O, Yiş R (2019). Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. Eurasian Journal of Medical Investigation, 3(2), 119 - 126. 10.14744/ejmi.2019.23641
Chicago Çalık Şebnem,ARI ALPAY,Tosun Selma,Okur Onur,Yiş Reyhan Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. Eurasian Journal of Medical Investigation 3, no.2 (2019): 119 - 126. 10.14744/ejmi.2019.23641
MLA Çalık Şebnem,ARI ALPAY,Tosun Selma,Okur Onur,Yiş Reyhan Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. Eurasian Journal of Medical Investigation, vol.3, no.2, 2019, ss.119 - 126. 10.14744/ejmi.2019.23641
AMA Çalık Ş,ARI A,Tosun S,Okur O,Yiş R Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. Eurasian Journal of Medical Investigation. 2019; 3(2): 119 - 126. 10.14744/ejmi.2019.23641
Vancouver Çalık Ş,ARI A,Tosun S,Okur O,Yiş R Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality. Eurasian Journal of Medical Investigation. 2019; 3(2): 119 - 126. 10.14744/ejmi.2019.23641
IEEE Çalık Ş,ARI A,Tosun S,Okur O,Yiş R "Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality." Eurasian Journal of Medical Investigation, 3, ss.119 - 126, 2019. 10.14744/ejmi.2019.23641
ISNAD Çalık, Şebnem vd. "Nosocomial Enterococcal Bacteremia:Predictors of Resistance and Mortality". Eurasian Journal of Medical Investigation 3/2 (2019), 119-126. https://doi.org/10.14744/ejmi.2019.23641